Neuroscience Antibodies and Assays

Global Neuroscience Antibodies and Assays Market to Reach US$9.8 Billion by 2030

The global market for Neuroscience Antibodies and Assays estimated at US$5.9 Billion in the year 2024, is expected to reach US$9.8 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 8.3% CAGR

The Neuroscience Antibodies and Assays market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Global Neuroscience Antibodies and Assays Market - Key Trends & Drivers Summarized

What Are Neuroscience Antibodies and Assays and Why Are They Crucial?
Neuroscience antibodies and assays are essential tools used in neuroscience research to study proteins, receptors, enzymes, and other molecules involved in the functioning of the nervous system. Antibodies are used to detect and bind to specific proteins or biomarkers related to neurological diseases, while assays help measure these biomarkers and study their effects on brain function. These tools are critical for understanding the molecular mechanisms underlying neurodegenerative diseases, brain injuries, psychiatric disorders, and developmental conditions such as autism.

The use of antibodies and assays in neuroscience is indispensable for identifying disease markers, enabling early diagnosis, and developing therapeutic interventions. For example, antibodies against amyloid-beta and tau proteins are widely used in Alzheimer’s research to study the buildup of these proteins in the brain. Similarly, assays are employed to measure the activity of neurotransmitters and other signaling molecules involved in brain function. By providing precise, reproducible data, neuroscience antibodies and assays are pivotal in advancing the understanding of complex brain diseases and developing targeted treatments.

How Is the Neuroscience Antibodies and Assays Market Evolving?
The neuroscience antibodies and assays market is evolving alongside advancements in molecular biology and diagnostic technologies. One of the major trends in this market is the increasing demand for high-quality, specific antibodies that can target complex proteins involved in neurological disorders. As neuroscience research delves deeper into neurodegenerative diseases, there is a growing need for highly specific antibodies that can differentiate between healthy and diseased tissues. Companies are developing more sophisticated antibodies that target post-translational modifications, protein isoforms, and disease-specific conformations, enhancing the precision of neuroscience research.

Additionally, the rise of multiplex assays, which allow for the simultaneous detection of multiple biomarkers in a single sample, is revolutionizing neuroscience research. These assays are particularly valuable in studying complex neurological conditions, where multiple signaling pathways and proteins are involved. Advances in assay technologies, such as next-generation sequencing (NGS) and mass spectrometry-based assays, are further driving growth in the market by enabling more comprehensive analysis of brain tissue, fluids, and cells. Automation and miniaturization of assays are also becoming more prevalent, improving throughput and reducing costs for researchers.

Which Research Areas Are Leading the Adoption of Neuroscience Antibodies and Assays?
Neuroscience antibodies and assays are being widely adopted in research focused on neurodegenerative diseases, neuroinflammation, and psychiatric disorders. Alzheimer’s disease research is one of the largest users of these tools, with antibodies targeting amyloid-beta plaques and tau tangles being essential for studying disease mechanisms and potential treatments. Parkinson’s disease research also relies heavily on antibodies and assays to study the accumulation of alpha-synuclein and other proteins implicated in the disease`s progression.

Neuroinflammation, a key factor in many neurological disorders, is another area driving the use of neuroscience antibodies and assays. Researchers are using these tools to measure inflammatory markers in the brain and spinal cord, providing insights into conditions such as multiple sclerosis, traumatic brain injury, and autoimmune diseases. Psychiatric disorders, such as schizophrenia and depression, are also major areas where antibodies and assays are being used to study neurotransmitter pathways and neural circuits, with the goal of developing more targeted and effective treatments.

What Are the Key Growth Drivers in the Neuroscience Antibodies and Assays Market?
The growth in the neuroscience antibodies and assays market is driven by several factors. One of the primary drivers is the increasing prevalence of neurodegenerative diseases, particularly in aging populations. As diseases like Alzheimer’s and Parkinson’s become more common, there is a growing need for biomarkers and diagnostic tools that can aid in early detection and treatment. Another key driver is the advancement of personalized medicine, which is creating demand for more specific and sensitive antibodies and assays tailored to individual patients` needs.

Technological advancements in assay platforms, such as multiplex assays and high-throughput screening, are also accelerating the growth of this market by enabling researchers to conduct more comprehensive studies. Additionally, the increasing investment in neuroscience research, coupled with government initiatives focused on mental health and neurological diseases, is fueling the expansion of this market. The rise of biopharmaceuticals and the development of targeted therapies for neurological conditions are further driving demand for neuroscience antibodies and assays in drug discovery and development.

SCOPE OF STUDY:

The report analyzes the Neuroscience Antibodies and Assays market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Offering (Consumables, Instruments); Technology (Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry, Other Technologies); End-Use (Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 11 Featured) -

• Abcam PLC
• BioLegend, Inc.
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• F. Hoffmann-La Roche AG
• GenScript Biotech Corporation
• Merck KgaA
• Rockland Immunochemicals, Inc.
• Santa Cruz Biotechnology, Inc.
• Siemens Healthineers
• Tecan Group Ltd.
• Thermo Fisher Scientific, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.